WO2007047863A2 - Crystals of laquinimod sodium, and process for the manufacture thereof - Google Patents

Crystals of laquinimod sodium, and process for the manufacture thereof Download PDF

Info

Publication number
WO2007047863A2
WO2007047863A2 PCT/US2006/040925 US2006040925W WO2007047863A2 WO 2007047863 A2 WO2007047863 A2 WO 2007047863A2 US 2006040925 W US2006040925 W US 2006040925W WO 2007047863 A2 WO2007047863 A2 WO 2007047863A2
Authority
WO
WIPO (PCT)
Prior art keywords
mixture
laquinimod sodium
ppm
laquinimod
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040925
Other languages
English (en)
French (fr)
Other versions
WO2007047863A3 (en
Inventor
Anton Frenkel
Eduard Gurevich
Avital Laxer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ567088A priority Critical patent/NZ567088A/en
Priority to DK06826297.1T priority patent/DK1937642T3/en
Priority to CN200680039201.6A priority patent/CN101291911B/zh
Priority to ES06826297.1T priority patent/ES2523762T3/es
Priority to RS20140629A priority patent/RS53666B1/sr
Priority to KR1020087011727A priority patent/KR101440982B1/ko
Priority to AU2006304672A priority patent/AU2006304672B2/en
Priority to EP06826297.1A priority patent/EP1937642B1/en
Priority to NZ592897A priority patent/NZ592897A/xx
Priority to PL06826297T priority patent/PL1937642T3/pl
Priority to HK08112048.9A priority patent/HK1117160B/en
Application filed by Teva Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc filed Critical Teva Pharmaceutical Industries Ltd
Priority to HRP20141160TT priority patent/HRP20141160T1/hr
Priority to BRPI0617477-9A priority patent/BRPI0617477A2/pt
Priority to SI200631860T priority patent/SI1937642T1/sl
Priority to JP2008536806A priority patent/JP5832716B2/ja
Priority to CA2625287A priority patent/CA2625287C/en
Publication of WO2007047863A2 publication Critical patent/WO2007047863A2/en
Publication of WO2007047863A3 publication Critical patent/WO2007047863A3/en
Priority to IL190137A priority patent/IL190137A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the mixture has a bulk density of at least 0.4 g/mL, at least 0.3 g/mL, or at least 0.2 g/mL.
  • the mixture has a tapped density of less than 0.8 g/mL, or less than 0.7 g/mL.
  • the anti-solvent is acetone.
  • the detection technique was ultraviolet absorption at 240nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2006/040925 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof Ceased WO2007047863A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
HK08112048.9A HK1117160B (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
CN200680039201.6A CN101291911B (zh) 2005-10-19 2006-10-18 拉奎尼莫钠晶体及其制备方法
ES06826297.1T ES2523762T3 (es) 2005-10-19 2006-10-18 Cristales de laquinimod sódico, y procedimientos para su fabricación
RS20140629A RS53666B1 (sr) 2005-10-19 2006-10-18 Kristali lakvinimod natrijuma i proces za njihovo dobijanje
KR1020087011727A KR101440982B1 (ko) 2005-10-19 2006-10-18 라퀴니모드 나트륨의 결정 및 이의 제조방법
AU2006304672A AU2006304672B2 (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
EP06826297.1A EP1937642B1 (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
NZ592897A NZ592897A (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
HRP20141160TT HRP20141160T1 (hr) 2005-10-19 2006-10-18 Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju
NZ567088A NZ567088A (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
DK06826297.1T DK1937642T3 (en) 2005-10-19 2006-10-18 Crystals of sodium laquinimod and the process for its preparation
PL06826297T PL1937642T3 (pl) 2005-10-19 2006-10-18 Kryształy lakwinimodu sodu i proces ich wytwarzania
BRPI0617477-9A BRPI0617477A2 (pt) 2005-10-19 2006-10-18 mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica
SI200631860T SI1937642T1 (sl) 2005-10-19 2006-10-18 Kristali natrijevega lakvinimoda in postopek za njihovo pripravo
JP2008536806A JP5832716B2 (ja) 2005-10-19 2006-10-18 ラキニモドナトリウムの結晶，及びその製造方法
CA2625287A CA2625287C (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof
IL190137A IL190137A (en) 2005-10-19 2008-03-13 Lacquinimod crystalline mixtures, pharmaceutical compositions containing them and ways to prepare them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72865705P 2005-10-19 2005-10-19
US60/728,657 2005-10-19

Publications (2)

Publication Number Publication Date
WO2007047863A2 true WO2007047863A2 (en) 2007-04-26
WO2007047863A3 WO2007047863A3 (en) 2007-06-28

Family

ID=37963287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040925 Ceased WO2007047863A2 (en) 2005-10-19 2006-10-18 Crystals of laquinimod sodium, and process for the manufacture thereof

Country Status (23)

Country Link
US (4) US7884208B2 (OSRAM)
EP (2) EP2687512A1 (OSRAM)
JP (3) JP5832716B2 (OSRAM)
KR (1) KR101440982B1 (OSRAM)
CN (3) CN101291911B (OSRAM)
AR (1) AR056708A1 (OSRAM)
AU (1) AU2006304672B2 (OSRAM)
BR (1) BRPI0617477A2 (OSRAM)
CA (1) CA2625287C (OSRAM)
DK (1) DK1937642T3 (OSRAM)
ES (1) ES2523762T3 (OSRAM)
HR (1) HRP20141160T1 (OSRAM)
IL (1) IL190137A (OSRAM)
NZ (2) NZ567088A (OSRAM)
PL (1) PL1937642T3 (OSRAM)
PT (1) PT1937642E (OSRAM)
RS (1) RS53666B1 (OSRAM)
RU (1) RU2415841C2 (OSRAM)
SG (1) SG10201508623RA (OSRAM)
SI (1) SI1937642T1 (OSRAM)
UA (1) UA92761C2 (OSRAM)
WO (1) WO2007047863A2 (OSRAM)
ZA (1) ZA200803527B (OSRAM)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2010001257A3 (en) * 2008-07-01 2011-03-31 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2011109526A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
WO2013148690A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
WO2013169746A2 (en) 2012-05-08 2013-11-14 Teva Pharmaceutical Industries Ltd. N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US8865742B2 (en) 2010-11-28 2014-10-21 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
EP3028572A1 (en) 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
EP3056205A1 (en) 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EP3064206A1 (en) 2009-08-10 2016-09-07 Teva Pharmaceutical Industries Ltd. Treatment of huntington's disease using laquinimod
EA025468B1 (ru) * 2009-07-30 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение болезни крона с применением лаквинимода
EP3213636A1 (en) 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP3225617A1 (en) 2012-02-16 2017-10-04 Teva Pharmaceutical Industries Ltd N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
US11065237B2 (en) 2013-11-15 2021-07-20 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SG10201508623RA (en) * 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
MX2011002033A (es) * 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
US20110217295A1 (en) * 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
MX2012010066A (es) * 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
EP2766020A4 (en) * 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR089862A1 (es) 2012-02-03 2014-09-24 Teva Pharma USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
CN104584098B (zh) 2012-09-03 2017-09-15 丰田自动车株式会社 碰撞判定装置和碰撞判定方法
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
JP7842983B2 (ja) * 2021-02-25 2026-04-09 学校法人神戸学院 腸管吸収用補助剤及びその利用方法
KR102876408B1 (ko) * 2022-01-24 2025-10-24 한국과학기술원 입도가 조절된 헥사나이트로스틸벤 타입 iv의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613574A (en) * 1898-11-01 Feed-regulator
US3024257A (en) * 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) * 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
CH687615A5 (de) 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US5912349A (en) * 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6256814B1 (en) 1997-09-19 2001-07-10 Cosco Management, Inc. Playyard
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) * 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
JP4980527B2 (ja) 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
PL199781B1 (pl) * 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
JP2002031610A (ja) * 2000-07-14 2002-01-31 Ajinomoto Co Inc 生体分子複合体の界面残基を同定する方法
US6307050B1 (en) * 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) * 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) * 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US7560557B2 (en) * 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
US7820145B2 (en) * 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2003300692A1 (en) 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
US8314124B2 (en) * 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG10201508623RA (en) * 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
EP2442651B1 (en) 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
ES2564931T3 (es) 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (en) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US20110217295A1 (en) 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
WO2011109526A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
MX2012010066A (es) 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EA201390074A1 (ru) * 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
US20120055072A1 (en) * 2010-09-08 2012-03-08 Rankin Sammy D Directional guide for fishing lures
CA2820586A1 (en) * 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1937642A4

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989473B2 (en) 2006-06-12 2011-08-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8383645B2 (en) 2006-06-12 2013-02-26 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US9340307B2 (en) 2007-12-20 2016-05-17 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
US8178127B2 (en) 2007-12-20 2012-05-15 Teva Pharmaceuticals Industries, Ltd. Stable laquinimod preparations
US8545885B2 (en) 2007-12-20 2013-10-01 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010001257A3 (en) * 2008-07-01 2011-03-31 Actavis Group Ptc Ehf Novel solid state forms of laquinimod and its sodium salt
US8354428B2 (en) 2008-07-01 2013-01-15 Actavis Group Ptc Ehf Solid state forms of laquinimod and its sodium salt
WO2010070449A3 (en) * 2008-12-17 2011-03-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
EP3028572A1 (en) 2009-06-19 2016-06-08 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
EA025468B1 (ru) * 2009-07-30 2016-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение болезни крона с применением лаквинимода
EP3064206A1 (en) 2009-08-10 2016-09-07 Teva Pharmaceutical Industries Ltd. Treatment of huntington's disease using laquinimod
US9585878B2 (en) 2009-08-10 2017-03-07 Teva Pharmaceutical Industries, Ltd. Treatment of BDNF-related disorders using laquinimod
WO2011109526A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
EP3213636A1 (en) 2010-07-09 2017-09-06 Teva Pharmaceutical Industries, Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP3056205A1 (en) 2010-07-09 2016-08-17 Teva Pharmaceutical Industries, Ltd. 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
US9102592B2 (en) 2010-11-28 2015-08-11 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
US8865742B2 (en) 2010-11-28 2014-10-21 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
EP3225617A1 (en) 2012-02-16 2017-10-04 Teva Pharmaceutical Industries Ltd N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
WO2013148690A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
WO2013169746A2 (en) 2012-05-08 2013-11-14 Teva Pharmaceutical Industries Ltd. N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl) amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US11065237B2 (en) 2013-11-15 2021-07-20 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US11690836B2 (en) 2013-11-15 2023-07-04 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US12419877B2 (en) 2013-11-15 2025-09-23 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Also Published As

Publication number Publication date
ZA200803527B (en) 2009-09-30
US7884208B2 (en) 2011-02-08
PL1937642T3 (pl) 2015-02-27
UA92761C2 (ru) 2010-12-10
US8673322B2 (en) 2014-03-18
EP1937642B1 (en) 2014-09-10
CN101291911A (zh) 2008-10-22
DK1937642T3 (en) 2014-12-15
AR056708A1 (es) 2007-10-17
PT1937642E (pt) 2014-11-25
CN107176923A (zh) 2017-09-19
IL190137A (en) 2015-06-30
KR101440982B1 (ko) 2014-09-17
ES2523762T3 (es) 2014-12-01
HRP20141160T1 (hr) 2015-01-16
JP2013100299A (ja) 2013-05-23
SI1937642T1 (sl) 2015-01-30
WO2007047863A3 (en) 2007-06-28
RS53666B1 (sr) 2015-04-30
AU2006304672A1 (en) 2007-04-26
CA2625287C (en) 2016-07-26
HK1117160A1 (en) 2009-01-09
US8647646B2 (en) 2014-02-11
JP5832716B2 (ja) 2015-12-16
EP1937642A2 (en) 2008-07-02
US20140171647A1 (en) 2014-06-19
JP2016020353A (ja) 2016-02-04
CA2625287A1 (en) 2007-04-26
RU2415841C2 (ru) 2011-04-10
AU2006304672B2 (en) 2013-01-10
RU2008119456A (ru) 2009-11-27
US20110112141A1 (en) 2011-05-12
NZ592897A (en) 2012-12-21
JP2009512708A (ja) 2009-03-26
IL190137A0 (en) 2008-08-07
US20070088050A1 (en) 2007-04-19
SG10201508623RA (en) 2015-11-27
BRPI0617477A2 (pt) 2011-07-26
CN101291911B (zh) 2014-08-13
EP2687512A1 (en) 2014-01-22
KR20080064978A (ko) 2008-07-10
CN103333107A (zh) 2013-10-02
US20110118308A1 (en) 2011-05-19
NZ567088A (en) 2012-06-29
EP1937642A4 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
US8673322B2 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
EP3524234B1 (en) Solid state forms of sofosbuvir
WO2013064307A1 (en) Ivabradine hydrochloride form iv
US9233927B2 (en) Crystals of laquinimod sodium and improved process for the manufacture thereof
US10793521B2 (en) Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof
CN112479912A (zh) 2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸晶型及其制备方法
HK1193404A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
HK1117160B (en) Crystals of laquinimod sodium, and process for the manufacture thereof
US8518935B2 (en) Amorphous besifloxacin solid
EA020944B1 (ru) Кристаллическая форма i соли розувастатина цинка
JP2025513893A (ja) ７，８－ジヒドロキシフラボンの結晶多形およびその調製方法
WO2025083656A1 (en) Novel crystalline form of lenacapavir sodium and processes for its preparation
WO2025032197A1 (en) Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile
AU2024323076A1 (en) Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile
CN118974018A9 (zh) 达罗他胺的晶型

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680039201.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190137

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006826297

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006304672

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 567088

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2625287

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008536806

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005084

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006304672

Country of ref document: AU

Date of ref document: 20061018

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087011727

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008119456

Country of ref document: RU

Ref document number: 1035/MUMNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: PI0617477

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080417

WWE Wipo information: entry into national phase

Ref document number: P-2014/0629

Country of ref document: RS